Psoriasis

Join Clinical Trials for Psoriasis

Join Clinical Trials for Psoriasis

General purpose: 

Research related to psoriasis may study genetic factors associated with the development of psoriasis, the role of the immune system in the development of psoriasis.

How various treatments for psoriasis affect the skin and joints, and how psoriasis increases the risk of other health problems, like diabetes, cancer, and heart disease.

Research may also look at new methods of treating psoriasis and any side effects that they cause.

About Psoriasis Clinical Trials (Click to Open)

Join Clinical Trials for Psoriasis

Psoriasis Clinical Trials

What do clinical trials for Psoriasis involve?

Clinical trials will vary widely in the information they collect, as well as the tests and procedures they use.

All of these factors will depend on individual study designs, which will differ greatly between trials. However, below is a list of common procedures and data that are frequently collected during a trial for psoriasis:

  • Subjective reporting by the patient as to the severity and tolerability of their psoriasis symptoms.
  • Visual inspection and evaluation of psoriasis skin lesions to determine their redness, thickness, and scaliness.
  • Skin biopsy
  • Photographs of psoriasis lesions.
  • Assessments of how psoriasis is affecting the patient’s quality of life.

Examples of Psoriasis- related research topics:

  • Studies comparing a conventional treatment for psoriasis with a newly developed drug to determine which is most effective.
  • Studies that investigate new treatments that are designed to help the skin resist to attacks from the immune system.
  • Studies designed to evaluate the use and effectiveness of laser treatment for psoriasis lesions.
  • Studies investigating the interaction between specific genes and environmental factors, and how that interaction increases the risk of developing psoriasis.
  • Studies that evaluate the effectiveness of treatments that target specific immune system cells that attack the skin and promote the inflammation see in psoriasis.

Suggested search terms for Psoriasis:  

“Psoriasis” “psoriasis treatment,” “psoriasis laser therapy,” “psoriasis arthritis,” “psoriasis cardiovascular,” “psoriasis symptoms,” and “psoriasis vitamins.”



Safety and Efficacy of Secukinumab in Mild Psoriasis


Condition:   Psoriasis
Interventions:   Drug: Secukinumab;   Drug: Placebo followed by Secukinumab
Sponsors:   James G. Krueger, MD, PhD;   Novartis
Recruiting


Efficacy and Safety Study of NP000888 in Subjects With Plaque and Nail Psoriasis


Condition:   Psoriasis
Interventions:   Drug: NP000888;   Drug: Vehicle
Sponsor:   Galderma R&D
Recruiting


BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test


Condition:   Psoriasis
Interventions:   Drug: BAY1003803;   Drug: Clobetasol propionate;   Drug: Betamethasone/calcipotriene
Sponsor:   Bayer
Completed


LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris


Condition:   Psoriasis Vulgaris
Interventions:   Drug: LEO 32731;   Drug: LEO 32731 Placebo
Sponsor:   LEO Pharma
Completed


The Corrona Psoriasis (PSO) Registry


Condition:   Psoriasis
Intervention:  
Sponsor:   Corrona, LLC.
Enrolling by invitation


The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis


Condition:   Psoriasis
Interventions:   Drug: Riboflavin;   Other: Placebo
Sponsor:   University of Michigan
Recruiting


Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients


Condition:   Psoriasis
Intervention:  
Sponsors:   University of Rochester;   Rheumatology Research Foundation
Active, not recruiting


Plaque Psoriasis Efficacy and Safety With Secukinumab


Condition:   Plaque Psoriasis
Intervention:   Biological: Secukinumab
Sponsor:   Novartis Pharmaceuticals
Completed


Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis


Condition:   Psoriasis
Intervention:  
Sponsors:   Northwestern University;   AbbVie
Recruiting


DFD06 Cream vs Comp01 Cream HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis


Condition:   Psoriasis
Interventions:   Drug: DFD06 Cream;   Drug: Comp01
Sponsor:   Promius Pharma, LLC
Completed


Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis


Condition:   Psoriasis
Interventions:   Biological: Adalimumab;   Biological: ABP 501
Sponsor:   Amgen
Completed


Secukinumab in TNF-IR Psoriasis Patients.


Condition:   Psoriasis
Interventions:   Biological: Secukinumab 150 mg;   Biological: Secukinumab 300 mg
Sponsor:   Novartis Pharmaceuticals
Completed


Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)


Condition:   Psoriasis
Intervention:   Biological: Secukinumab
Sponsor:   Novartis Pharmaceuticals
Completed


Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.


Condition:   Psoriasis
Intervention:   Drug: Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]
Sponsors:   University of North Carolina, Chapel Hill;   AbbVie
Completed


AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis


Condition:   Psoriasis
Interventions:   Drug: AN2728 ointment, 2%;   Drug: Ointment Vehicle
Sponsor:   Pfizer
Completed


Trial of CF101 to Treat Patients With Psoriasis


Condition:   Plaque Psoriasis
Interventions:   Drug: CF101;   Drug: Placebo
Sponsor:   Can-Fite BioPharma
Completed


The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis


Condition:   Psoriasis
Interventions:   Drug: Calcipotriene Foam;   Drug: Vehicle Foam
Sponsors:   Stiefel, a GSK Company;   GlaxoSmithKline
Completed


Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis


Condition:   Psoriasis
Intervention:   Drug: AMG 827
Sponsor:   Amgen
Terminated


Fluphenazine Hydrochloride for Psoriasis


Condition:   Psoriasis
Interventions:   Drug: Fluphenazine;   Drug: Placebo
Sponsors:   Tufts Medical Center;   Immune Control
Completed


Developing A Validated Measure of the Impact of Psoriasis on Chronic Quality of Life


Condition:   Psoriasis
Intervention:  
Sponsor:   Massachusetts General Hospital
Completed


Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis


Condition:   Psoriasis
Interventions:   Drug: AN2728;   Drug: AN2728 Ointment Vehicle
Sponsor:   Pfizer
Completed


Dose Ranging Study of the Safety and Efficacy of R115966 in Plaque Psoriasis


Condition:   Psoriasis
Intervention:   Drug: Talarozole
Sponsor:   Stiefel, a GSK Company
Completed


Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies


Condition:   Psoriasis
Interventions:   Drug: U0267;   Drug: Vehicle
Sponsors:   Stiefel, a GSK Company;   GlaxoSmithKline
Completed


Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis


Condition:   Psoriasis
Interventions:   Drug: CC-10004;   Drug: Placebo
Sponsor:   Celgene
Completed


Refine Your Search Advanced Search